New drug
Garadacimab for hereditary angioedema
- Aust Prescr 2026;49:256-7
- 1 December 2026
- DOI: 10.18773/austprescr.2026.052
Background: Hereditary angioedema (HAE) is a rare genetic disorder characterised by recurrent swelling that most commonly affects the skin, gastrointestinal tract and upper airways. Most cases are caused by deficiency or dysfunction of the complement protein C1-esterase inhibitor (type 1 and type 2 HAE, respectively), resulting in excessive bradykinin production and increased vascular permeability.1 Symptoms range from non-pruritic and non-pitting oedema of the skin to severe abdominal pain and potentially life-threatening swelling of the upper airways.1 HAE attacks are typically self-limiting but unpredictable, and may be triggered by factors such as stress, trauma, infection and hormonal changes.1
There is no cure for HAE; therefore, treatment aims to reduce the severity and frequency of attacks through acute treatment, short-term prophylaxis before triggering events and long-term prophylaxis.2 Before the approval of garadacimab, long-term prophylactic options in Australia included human C1-esterase inhibitor (Berinert) and lanadelumab (Takhzyro; a fully human IgG1 monoclonal antibody against plasma kallikrein).3,4
Mechanism of action: Garadacimab is a first-in-class, fully human IgG4 recombinant monoclonal antibody that inhibits activated factor XII. Activated factor XII is an upstream mediator in the kallikrein–kinin pathway that regulates bradykinin production. Inhibition of activated factor XII blocks the production of bradykinin, thereby preventing HAE-associated inflammation.5
Clinical trials: Garadacimab was evaluated in the phase 3 VANGUARD trial, a multicentre randomised double-blind placebo-controlled trial in patients aged 12 years and older with type 1 (88%) or type 2 (13%) HAE.5 Patients had to have experienced at least 3 HAE attacks in the previous 3 months and were required to stop other long-term prophylactic treatments for HAE. People using other monoclonal antibodies or estrogen-containing therapies were excluded.
Thirty-nine patients received subcutaneous garadacimab (400 mg loading dose followed by 200 mg once monthly) and 25 patients received placebo for 6 months. Medications for acute treatment of HAE attacks were used if required.5
The mean number of HAE attacks per month was significantly lower in the garadacimab group than in the placebo group (0.27 versus 2.01 attacks per month, representing an 87% reduction). The mean number of attacks per month that required acute treatment was also lower with garadacimab (0.23 versus 1.86 attacks per month).5 Over the 6-month treatment period, 62% of patients receiving garadacimab remained attack-free, compared with none of those receiving placebo.5
Adverse effects: Common adverse effects of garadacimab in the trial included upper respiratory tract infections (10% garadacimab versus 8% placebo) and nasopharyngitis (8% versus 4%).5 Injection-site reactions were uncommon and similar in the garadacimab and placebo groups.5,6
Dosage and administration: An initial loading dose of garadacimab 400 mg (two 200 mg subcutaneous injections) is given on day 1, followed by 200 mg once monthly. Garadacimab injections can be self-administered into the abdomen or thigh, or into the upper arm if it is administered by another person. The injection site should be rotated each time.
Precautions: Because of its mechanism of action, garadacimab may interfere with activated partial thromboplastin time assays, but this has not been observed to increase bleeding risk.7
As with other monoclonal antibodies, hypersensitivity reactions may occur.
Use in pregnancy and breastfeeding: Monoclonal antibodies such as garadacimab may cross the placenta, particularly during the third trimester.7 Data are limited on the use of garadacimab in pregnancy and harms to the pregnant person or fetus cannot be excluded.
Human IgG antibodies are known to be excreted in breast milk in the first few days after birth.7 The benefits of breastfeeding should be considered alongside the mother’s clinical need for garadacimab and the potential adverse effects on the infant.
Place in therapy: The management of HAE is evolving, with garadacimab providing another option for long-term HAE prophylaxis. Indirect comparisons suggest that garadacimab may provide greater reductions in moderate to severe HAE attacks than lanadelumab and human C1-esterase inhibitor;8,9 head-to-head trials are needed to confirm these findings. An advantage of garadacimab is that it only requires once-monthly administration (after the initial loading dose), whereas lanadelumab requires 2 injections every 2 to 4 weeks and human C1-esterase inhibitor requires twice-weekly subcutaneous injections.3,4
Practice points: Garadacimab is indicated for long-term HAE prophylaxis and should not be used to treat acute attacks. Patients on prophylactic therapy may still experience breakthrough attacks and patients should ensure they have access to an approved rescue medicine.
Patients and caregivers should be trained in the correct administration of subcutaneous injections.
All patients, especially children, should have a personalised HAE management plan that explains how to recognise and treat breakthrough attacks and what to do if rescue medicines are ineffective. Any attack involving the upper airways requires urgent medical attention.4
This new drug comment was finalised on 20 October 2026. It was prepared by Sherilyn Wong, Clinical Editor, Australian Prescriber, and reviewed by Mitchel Hurlbert, Clinical Pharmacology Advanced Trainee, St Vincent’s Hospital Sydney.
At the time this new drug comment was prepared, the Australian Public Assessment Report was available from the Therapeutic Goods Administration. The sponsor did not provide the Clinical Evaluation Report.
This article is peer reviewed.
Australian Prescriber welcomes Feedback.
The new drug comments in Australian Prescriber are prepared by the editors and reviewed by subject matter experts. Some of the views expressed on newly approved products should be regarded as preliminary, as there may be limited published data at the time of publication, and little experience in Australia of their safety or efficacy. Before new drugs are prescribed, it is important that more detailed information is obtained from the approved product information, a medicines information centre or some other appropriate source.
Report all suspected adverse reactions to new drugs to enable continued monitoring of their benefit–harm balance.